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While expression of intracellular adhesion molecule 1 (ICAM-1; CD54) is associated with chronic 
inflammation and autoimmune disease, and is also found on some tumours arising from ICAM-1-negative 
tissues, in apparently normal tissues it is restricted to a few cell types. Levels of constitutive ICAM-1 
expression correlate with the levels of ICAM-1 mRNA. In order to identify regions of the gene regulating 
its constitutive expression, 5.8 kb of the 5' upstream region was studied in 16 human cell lines using 
transient transfection of reporter-gene constructs. Three enhancing and one silencing region were ob­
served. While the enhancer upstream of position —1352 was active in all cells investigated, the inhibitory 
influence of a silencer region between positions —339 and -290 was observed only in 50% of the cells. 
All cells expressing low levels of ICAM-1, such as may occur in many tissues in vivo, lacked an active 
silencer. In contrast to the ICAM-1 low-expressing cells, cell lines with high constitutive ICAM-1 levels, 
as well as those with no ICAM-1 expression, showed an active silencer. Thus, ICAM-1 constitutive 
expression seems to be regulated in two different ways. The fact that silencer and enhancer activities 
were observed in both strongly positive and negative ICAM-1 cells, suggests that constitutive ICAM-1 
expression is regulated by a balance of enhancing and silencing transcription factors and possible addi­
tional elements.
Keywords. Promoter region; regulatory sequences; transfection; luciferase plasmids; cell-adhesion mole­
cule.
The glycoprotein intercellular adhesion molecule 1 
(ICAM-1, CD54) is a member of the immunoglobulin supergene 
family [1, 2] and a cell-adhesion molecule that serves as a 
counter-receptor for a number of molecules including the leuko­
cyte p2 integrins LFA-1 (CDlla) and MAC-1 (CDllb) and the 
T-cell leukosialin CD43 [3-9]. The interaction between LFA-1 
and ICAM-1 is an important step in the development of immune 
responses, mediating the migration of lymphocytes into the 
tissues, playing a costimmulatory role in T-cell activation and 
strengthening interactions between effector cells and their targets 
[10—12]. While upregulation of ICAM-1 can be induced in 
essentially any cell type by exposure to cytokines, in normal 
tissues detectable constitutive ICAM-1 expression is restricted 
to lymphoid follicle germinal centres, some vascular endothelia 
and to occasional cells in thymus, tonsils and proximal tubules 
in the kidney [3,13 — 16]. The association of high levels of endo­
thelial and epithelial ICAM-1 expression with a wide range of 
autoimmune diseases suggests that ICAM-1 plays an important 
role in the initiation and maintenance of these diseases [17—20]. 
The expression of ICAM-1 on solid tumours derived from 
ICAM-1-negative tissues, appears to be largely independent of 
the degree of leukocyte infiltration and to be rather a question 
of the tumour type. Thus, ICAM-1 expression is frequent on 
malignant melanomas and renal cell carcinomas, is found only 
on a minority of gastric carcinomas and breast carcinomas and
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Abbreviations. ICAM-1, intercellular adhesion molecule-1 ; RLU, 
relative light units; MFI, mean fluorescence intensity.
very rarely on colorectal carcinomas [21—24]. While the role of 
ICAM-1 expressed on tumours remains unclear, it has been 
shown in several cases to have a prognostic significance [21, 
24]. Clearly, a better understanding of how constitutive ICAM-1 
expression is regulated is important in the context of both auto­
immunity and host-tumour interactions. To understand how con­
stitutive ICAM-1 expression is controlled, reporter-gene con­
structs of the 5' regulatory region of the ICAM-1 gene have been 
transfected into various cell lines [28—32]. On the basis of 
studies on two cell lines, a silencing region that is active in 
ICAM-1-negative-cells, but inactive in ICAM-1-expressing cells 
has been reported [30]. In the study presented here, the expres­
sion of ICAM-1 promoter-region constructs have been charac­
terised in 16 human cell lines deriving from different tissues. 
Although this silencer activity was found in 50% of the cells, it 
did not correlate with either the ICAM-1 phenotype or the cell 
type. Furthermore, a constitutively enhancing region between 
positions —2400 and —1352 that could override the silencer, 
and two additional positively acting sites downstream of posi­
tion —277 were detected. A comparison of the activity of the 
5' region in ICAM-1-positive and ICAM-1-negative cell lines 
suggests that two distinct patterns of constitutive ICAM-1 gene 
regulation exist; one that is active in cells expressing low levels 
of ICAM-1 and one that is active in cells that are either negative 
for ICAM-1 or express high levels of ICAM-1.
MATERIALS AND METHODS
Cell culture. Human cell lines were established in our labo­
ratory or obtained from the American Type Culture Collection,
440 Jahnke et al. (Eiu\ J. Biocheni. 228)
and were cultured in RPMI 1640 medium (Biochroin) contain­
ing 5% fetal calf serum, 1 mM sodium pyruvate, 2 mM 1-gluta­
mine, 100 li/ml streptomycin and 100 U/ml penicillin.
Immunofluorescence and FACScan analysis. The first 
antibody used was either P3.58BA-14 anti-ICAM-1 [33] or 
upc 10 myeloma protein (Sigma) as isotype control. The second 
anti-(mouse Ig) serum was fluoroisothiocyanate labelled (Dako- 
patts F261). The cells were examined under a fluorescence 
microscope and flow cytometry was performed using a FACS­
can (Becton Dickinson).
Northern-blot analysis. Total RNA was prepared using a 
modification of the caesium trifluoracetate method (Pharmacia). 
20 |Lig RNA/lane were denatured in formaldehyde, separated on 
a 1.2% agarose/formaldehyde gel [34], and transferred to a 
Hybond-N membrane (Amersham). The 690-bp 1CAM-1 cDNA 
Pstl fragment, labelled with [«-32P]dATP (Amersham) using 
random priming [35], was used as a probe. Hybridisation and 
washing were carried out as described [21]. Hybridisation with 
an oligonucleotide (5' CCCTGGTGAC CAGGCGGCCA 
ATACGGCCAA TCCGTTGACT CCGACTTTCC AC 3') from 
the first exon of the glyceraldehyde-3-phosphate dehydrogenase 
gene [36] was used as an internal standard. The oligonucleotide 
was end-labelled with [a-32P]dATP (Amersham) using terminal 
dideoxynucleotidyl transferase (Gibco-BRL) and the membrane 
was hybridised at 68°C in 5 XNaCl/Cit (1 Xconsists of 150 mM 
sodium citrate, 15 mM NaCl, pH7.0)/10XDenhardt’s solution/ 
7% SDS/10 mM sodium phosphate, pH 7.0/10% dextran sul­
phate/100 ng/ml salmon sperm DNA. The membrane was 
washed first in 3 X  NaCl/Cit/10 X Denhardt’s solution/5 % SDS/
10 mM sodium phosphate, pH 7.0, at the hybridisation temper­
ature, then in 1 X  NaCl/Cit/1 % SDS at room temperature.
Construction and purification of luciferase reporter-gene 
plasmids. All constructs except pIC-5800, pIC-2400 and pIC- 
277JTATA1, have been described previously (Fig. 1 B) [28]. 
pIC-5800 was constructed by digestion of X clone PBL 11 
(Fig. 1 A; in [37] Table 1 oligonucleotides B and C were mistak­
enly shown as reactive) with Sail, isolation of the 5,8-kb frag­
ment and ligation with promoterless pXP-2 (kindly provided by
S. K. Nordeen, Denver, USA) [38], also cut with SalL The 2.4- 
kb fragment was excised with Sail from X clone HWB 3R1 
(Fig. 1 A) and inserted into pXP-2. The fact that the clone was 
full length and in the correct orientation was confirmed by re­
striction enzyme digestion and sequencing of the cloning sites. 
pIC-277zfTATAl was constructed by deleting the Nhel—Sstl 
fragment of pIC-277, then sequenced [28]. Plasmid DNA was 
purified by separation over two caesium chloride gradients [39]. 
To exclude transfection differences due to variability in DNA 
purification, at least two different batches were used in these 
studies.
Transient transfection and detection of luciferase activity 
of reporter-gene constructs. For transfection of the reporter- 
gene constructs, the Transferrinfection system (Serva) was used. 
250000 cells were grown for 18 h in six-well plates (11 cm2, 
Falcon/Becton Dickinson). The supercoiled plasmid DNA (equi- 
molar amounts of each plasmid made up to 12 jig total DNA 
with pXP-2) diluted in HBS (20 mM Hepes, 150 mM sodium 
chloride, pH 7.3) was complexed by the poly-(L)—lysine-ferrous 
conjugate (16 p.g/12 fig total DNA) for 30 min at room temper­
ature, in a total volume of 0.5 ml. This was added to the cells, 
together with 2 ml HBS medium containing 125 jliM chlo- 
roquine. Following 6 h exposure, the cells were rinsed once with 
warmed RPMI 1640 medium and incubated for a further 24 h in 
fresh RPMI 1640 medium. Cells were washed once with NaCl/ 
Pi (15 mM potassium dihydrogen phosphate, 80 mM disodium 
hydrogen phosphate, 139 mM NaCl, pH 7.2) and lysed with 
125 |il lysis buffer of the luciferase assay system (Promega). 20 jil
cell lysate was measured for 10 s in a luminometer (LB9501, Ber- 
told Lumat) injecting 100 \d luciferase assay reagent.
To standardise the measured relative light units (RLU), the 
protein content was determined according to the method of 
Bradford [40] using the Biorad protein assay reagent (Biorad). 
The standardised absolute luciferase activity was calculated by 
dividing the observed RLUs in 20 jil cell lysate by the protein 
content. Previous experiments had shown that correcting for the 
protein content gave rise to the same expression patterns as stan­
dardisation with the cotransfected plasmid CDM8/?Gal (kindly 
provided by A. Leutz, Berlin, Germany) and detection of /J-ga- 
lactosidase activity. To avoid possible titration effects when 
using two promoter-containing plasmids, the protein standardi­
sation approach was routinely used. Each transfection was 
carried out in triplicate and at least three independent experi­
ments were performed.
Transfection of genomic clone HWB 3R1. Transfection 
using lipofectin (Gibco-BRL) was performed as described [37], 
but using 5 fig X DNA. ICAM-1 expression was determined 
by immunofluorescence and immunoperoxidase staining. The 
highest ICAM-1 expression was observed on day 3 after trans­
fection.
Computer analysis. All published ICAM-1 sequences 
[29, 31, 32, 37] upstream of exon 1 were combined into one 
sequence extending from positions -1816 to +41 (the down­
stream transcription start site was set +1) [31]. Searches for 
consensus sequences in this ICAM-1 sequence were performed 
on a VAX/VMS machine with the GCG program package. Com­
parison of the transcription factors database (TFD, release 7.3) 
with the ICAM-1 sequence was performed on a Macintosh PC 
with the Macmolly program package.
RESULTS
Classification of human cell lines by their ICAM-1 expres­
sion. ICAM-1 cell surface expression was evaluated using flow 
cytometry on 16 cell lines of diverse histological origin 
(Table 1). The cells could be divided into three groups on the 
basis of their A mean fluorescence intensity (//MFI), i.e. MFI of 
anti-(ICAM-l) IgG binding minus MFI of isotype control bind­
ing: ICAM-1-negative cell lines (zfMFI<30), ICAM-1-positive 
cell lines (JMFI 30-200) and strongly ICAM-1-positive 
(¿iMFI>200). The fluorescence intensities of the negative con­
trol upclO (dotted line) and the anti ICAM-1 IgG (P3.58BA-14, 
solid line) are shown in Fig. 2 as examples of each of the three 
groups.
Northern-blot analysis confirmed that the cell surface levels 
of ICAM-1 reflect differences in steady-state mRNA levels 
and suggest that ICAM-1 expression is primarily regulated at 
the transcriptional level. As shown in Fig. 2C, cell lines 293, 
Colo320DM and H4 that show no ICAM-1 cell surface expres­
sion, express no detectable ICAM-1 mRNA. However, strongly 
positive cells Mel JuSo, A-375 and WM266-4 have high levels 
of mRNA, and the weakly positive cell line KATO expresses 
lower mRNA levels.
Reporter-gene constructs reveal silencing and enhancing 
elements differentially active in cells with distinct ICAM-1 
expression levels. To examine whether differences in the activ­
ity of tram-acting proteins binding to the 5'-region DNA are 
responsible for differences in ICAM-1 expression, reporter-gene 
constructs containing up to 5.8 kb of the 5' region of the human 
ICAM-1 gene were tested by transient transfection for expres­
sion in the various cell lines. Each transfection was performed 
in triplicate in at least three independent experiments (with the
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Fig. 1. Genomic structure of human ICAM-1 and reporter-gene constructs, (A) Genomic structure of the ICAM-1 gene with exons 1-7 
(El — E7). Genomic X clone HWB 3R1 contains all exons and portions of the 5' untranslated region as well as of the 3' untranslated region, while 
PBL 11 reaches from position -5800 (the G of the downstream TGA transcription start site was set +1) to approximately position +8000 in intron 
2. HS, DNAse-1 hypersensitive site at position —1550. C, Sacl', E, EcoKl; P, Pstl; B, BglU; X, Xhol\ H, Hindlll; S, Sail. (B) The region from 
position +1 to —5800 was cloned into luciferase reporter-gene construct pXP-2 (see Materials and Methods). Dotted lines, internal deletions. The 
TATA boxes are indicated as TATA1 (downstream) and TATA2 (upstream), while the other black boxes show potential transcription-factor-binding 
sites. TRE, 12-0-tetradecanoylphorbol-13-acetate-responsive element, SP1, Spl ; AP2, AP-2; NF-kB, NF-/cB. A, Accl; H, Hindlll; S, Smal; P, 
Pstl; N, Ncol.
exception of simian-vin.is-40-transformed fibroblast cell line 
HF/SV40, which was transfected only twice), using different 
DNA preparations. The measured luciferase activity (absolute 
expression, RLU/|ig protein) of plasmid pIC-174, containing 
the 174-bp ICAM-1 promoter region in front of the luciferase 
reporter-gene, is shown in Table L The absolute luciferase activ­
ity measured with pIC-174 differed greatly dependent on the 
cell line, however independent of the ICAM-1 expression. The 
luciferase-containing promoterless cloning vector, pXP-2 [38], 
was used as a negative control. Its activity in all cell lines was 
below 5 RLU/jug protein and was not subtracted from test 
values.
The luciferase expression of a set of deletion constructs of 
the ICAM-1 5' region was examined in each of the cells in 
Table 1. The luciferase activity of pIC-174 was set at 100% rela­
tive expression, and compared to the other constructs, shown in 
Fig. 2 A and B for representative cell lines. In all cells examined, 
cells strongest luciferase expression was observed with construct 
pIC-5800 containing the longest 5" region of the ICAM-1 gene. 
Its activity was 1.2-2.5-fold higher than luciferase expression 
by pIC-174. Deletion of the region upstream of position -1352 
resulted in decreased reporter-gene activity in all cells (only
0.5—0.125 of the activity of pIC-5800), suggesting that this re­
gion has an enhancing influence on ICAM-1 expression. Further 
deletion divided the investigated cell lines into two groups. The 
level of expression driven by the constructs spanning the region 
between positions —1352 and —339 was nearly constant in both 
groups but on different levels. In group-A cells (Fig. 2A), plas­
mids containing DNA upstream of position —174 and down­
stream of position -1352 generated luciferase expression that 
was reduced by at least 50% as compared to that of the pIC-174 
plasmid. Type-B cells, in contrast (Fig. 2B), revealed nearly the 
same luciferase expression with plasmids spanning the entire 
region between positions -1352 and +1. These results indicate 
the presence of an inhibitory element between positions —339 
and —174 that is active only in type-A cells. All cells in Table 1 
were found to fall either into group A or group B (partially data 
not shown) and, comparing this characteristic with their ICAM-1 
cell surface expression, revealed an unexpected correlation. All 
type-B cells (WM115, IgR37, KATO, BT20, SW403, LS180, 
HepG2 and HF/SV40) expressed low levels of ICAM-1. 
However, type-A cells, in which the inhibitory effect of the re­
gion between positions —339 and -174 could be seen (Mel 
JuSo, WM266-4, A-375, HMCB, 293, FI4, Colo320DM and
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Table 1. ICAM-1 cell surface expression and luciferase activity of construct pIC-174 in the examined human cell lines. z/MFT — difference 
MFI between ICAM-l-specific antibody and isotype control. ¿iMFI>30 was considered as positive, n — number of independent experiments. RLU/
Hg protein ~ RLU/jig total protein.
Cell line Tissue ¿ÍMFI n pIC-174 expression
RLU/|ig protein
il
Mel JuSo melanoma 284 ± 33 11 2308 ± 699 8
WM266-4 melanoma 295 ± 31 9 2880 ± 168 5
A-375 melanoma 285 ± 68 4 212 ± 54 3
WM115 melanoma 143 ± 35 3 15 ± 3 3
KATO stomach 156 ± 30 5 22 ± 9 4
HF/SV40 fibroblast 157 ± 49 2 17 ± 2 2
BT20 breast 141 ± 52 3 59 ± 7 4
HepG2 liver 121 ± 52 3 549 ± 124 3
LSI 80 colon 67 ± 6 3 44 ± 5 3
IgR37 melanoma 39 ± 13 3 101 ± 29 3
SW403 colon 39 ± 2 3 14 ± 2 3
293 fetal kidney 10 ± 20 8 2492 ± 663 8
H4 neuroglioma 9 ± 14 5 99 ± 11 5
HMCB melanoma 5 ± 12 6 67 ± 26 3
Colo320DM colon 5 ± 16 5 2164 ± 568 5
Lo Vo colon - 8 ± 7 5 2878 ± 523 5
Lo Vo), were either strongly ICAM-1-positive or ICAM-1 nega­
tive.
Location of one silencing and three enhancing regions. By
transfecting additional ICAM-1 5'-upstream-region constructs 
into the melanoma cell line Mel JuSo, the regulatory elements 
were localised. Mel JuSo is a strongly ICAM-1-positive type-A 
cell line (Table 1), that shows the inhibitory influence of the 
region between positions -339 and -174 (Fig. 3). High lucifer- 
ase expression was obtained with plasmids pIC-5800, containing 
5.8 kb of the ICAM-1 5' upstream region, and pIC-2400 contain­
ing 2.4 kb of the ICAM-1 5' upstream region (Fig. 3). Deletion 
of the region upstream of position -1352 reduced activity to 
approximately 10% of that of pIC-2400, indicating an enhancer 
between positions —2400 and —1352 that is able to override the 
silencer downstream.
While plasmids containing the ICAM-1 upstream region 
from positions —1352 to -339 showed an identical low level 
of reporter-gene activity, deletion of the region between posi­
tions —339 and -174 caused a fourfold increase of reporter- 
gene expression, similar to the expression patterns shown in 
Fig. 2A. This region was more closely examined using the con­
structs pIC-290/-6 and pIC-277 (Fig. IB). Deletion of the region 
from nucleodites —339 to —290, that includes the upstream 
TATA box [29], caused a sevenfold increase in reporter-gene 
activity (Fig. 3), suggesting that the deleted region contains a 
binding site for the inhibitory element active in Mel JuSo. 
Deletion of a further 13 bp from positions —290 to -277 con­
taining a 12-O-tetradecanoylphorbol-13-acetate-responsive ele­
ment TRE [28], caused no significant change in luciferase ex­
pression. It therefore appears that the inhibition of the reporter- 
gene expression mediated by the region between positions 
-339 and —174 is due to a silencer-binding site located between 
positions “ 339 and —290. The sequence between positions 
—321 and -302 revealed homology to several known silencer- 
binding motifs (Table 2, see Discussion).
Deletion of the next 100 bp to position -174 still left an 
active promoter, but with a nearly twofold decreased activity in 
comparison to that of pIC-277. An internal deletion of posi­
tions —227 to —136 in pIC-277z/Sma had nearly no effect on 
the luciferase expression in comparison to that of pIC-277
(Fig. 3), suggesting that the region ranging from positions 
-277 to —227 may be responsible for the enhanced expression j 
of pIC-277ziSma and pIC-277 relative to that of pIC-174.
This site contains a putative AP-2 site at position -271 
(GCCTGGCC) and a potential NF-/cB site at position -239
[41]. 'i
Full activity of the core promoter depended on the presence i 
of the downstream TATA box (at -30 TATAAA) and the region 
between positions —108 and -34, containing putative Spl 
(-59 CCGCCC) and AP-2 (-48 CCCCCAGG) sites [41]. While
pIC-277 showed full promoter activity, deletion of the region 
between positions —108 to —34 (pIC-277/lAP2) led to a nearly 
complete loss (more than 90%) of promoter activity with only 
slightly higher levels of luciferase activity than plasmid pIC-34, 
that contains only the downstream TATA box (Fig. 3).
Deletion of the downstream TATA box from pIC-277 (con- * 
struct pIC-277JTATAl) reduced reporter-gene activity to back­
ground levels. However, promoter activity could be restored by 
the addition of sequences further upstream (plasmid pIC- 
1352zlTATAl), suggesting that the upstream TATA box at 
position —313 can also function as a transcription-initiation site
(Fig. 3).
The full-length clone mediates ICAM-1 expression in 
ICAM-1-negative cell lines. HWB 3R1 is a full-length X clone, 
containing 15.5 kb of the human ICAM-1 gene including all 
seven exons, six introns, a 2.4-kb upstream region and a 1.5-kb 
3' untranslated region (Fig. 1 A) [37]. This clone was transfected 
into several ICAM-1-negative cell lines including H4, 
Colo320DM, 293 and HMCB. In all cell lines, ICAM-1-express­
ing cells were found both by immunofluorescence and by A 
immunoperoxidase staining (data not shown). No positive cells 
were observed following transfection of X DNA alone. Clone j 
HWB 3R1, therefore, contains all information necessary for 
functional ICAM-1 expression, however does not reflect the in 
vivo regulation.
While human ICAM-1 expression can be induced on a vari­
ety of cell types in apparently normal tissues, it is restricted to
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Fig. 2. Correlation between the expression pattern of the ICAM-1/Iuciferase constructs and the ICAM-1 cell surface expression. The right 
panels of each figure in (A) and (B) show, for representative cell lines, the cell surface expression of ICAM-1 (solid line) stained with mAb 
P3.58BA-14 compared to the isotype control antibody upclO (dotted line) as fluorescence against cell number. The left side shows the relative 
luciferase expression. The expression of plasmid pIC-174 was set 100% and the activity of the other constructs was compared to this. Plasmid 
pXP-2 was used as negative control. The standard deviation of at least three independent experiments (see also Table 1) is indicated. (C) Northern 
blot. 20 j_ig total RNA of representative cell lines was electrophoresed, blotted and hybridised with either an ICAM-l~specific 690-bp Pstl fragment 
or an oligonucleotide specific for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. The size of the up to three ICAM-1 mRNAs (3.4, 
2.6 and 1.7 kb) are indicated.
a few cell types [3, 13 — 16]. However, strong ICAM-1 expres­
sion is found on some solid tumours [21—23], As reported by 
Simmons et al. [1] and confirmed here, these different ICAM-1 
protein levels reflect differences in ICAM-1 mRNA, indicating 
that this molecule is primarily regulated at the level of transcrip­
tion. Transient transfection of reporter-gene constructs revealed 
four regions that appear to be important and indicated that con­
stitutive expression is regulated in two different ways.
The highest levels of reporter-gene expression were ob­
served with the construct pIC-5800. Deletion of the region be­
tween positions -5800 and —1352 led to at least a 50% reduc­
tion in luciferase activity in all examined cell lines. Using addi­
tional constructs, the region mediating this enhancing effect was 
localised between positions -2400 and -1352, a region pre­
viously shown to contain a DNAsel hypersensitive region 
around position —1550. This site was reported in two ICAM-1-
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Table 2. Comparison of the ICAM-1 silencing region with published silencer-binding sequences. The silencing region of the human ICAM-1 
promoter (positions —  339 to —290) shows striking homologies between positions —321 and —302 to different published silencer-binding regions. 
Bold letters indicate nucleotides identical to the ICAM-1 sequence. The arrows indicate an imperfect inverted repeat. Complementary, complementary 
to the published sequence.
Sequence Source Reference
5 ' -ATTTAAAAGTACTTAATAAAC-3 ' 
TATGAAAAGTAGTTATGAAAA 
AAAATTA.. TATTAAA
CTTCATAAC
CAAAAGATAGA
CAAAATACAATTA
AAATAAA
TATAAAATTATA
ICAM-1 promoter (positions “ 321 to —302)
HPV-18 promoter, complementary
human multiple histocompatability complex class I
human «-fetoprotein
mouse albumin gene, complementary
mouse N-ras, complementary
rat prolactin gene (position —322)
rat prolactin gene, complementary (position —290)
37
51 
47
52
53
54
55 
55
positive cell lines [32], but is also detectable in the ICAM-1 - 
negative cell line LoVo (unpublished observations). An exami­
nation of the ICAM-1 sequence between positions —1816 and
— 1352 for potential transcription-factor-binding sites revealed, 
at position -1469 (GGGCAAGAGCT), homology to the re­
verse sequence of an antisilencer-binding site identified in the 
chicken vimentin gene (TGCCAAGAGCA) [42] as well as 
homology at position —1783 (CC ACC AC ACC) to an enhancer 
motif observed in the rat neu gene (GGTGGGGGGG) [43]. 
Two potential NF-/cB-binding sites at position —1743 
(GGGGTCTCCC) and position -1397 (GGGGCGTCCC), two 
possible Spl sites [positions —1452 (CCGCCC) and —1352 
(GGCGGG)] and one putative AP-2 site at position —1415 
(CCCAGGCC) were also identified in this region [41].
Further deletion from —1352 to —339 bp led to little or no 
change in reporter-gene activity in the cells examined. In the so 
called type-B cells, deletion of the region between positions 
—339 and —174 also did not alter the luciferase activity. In con­
trast, in the type-A cells, deletion of this region led to an 
increase in luciferase expression up to fourfold, indicating the 
presence of an active silencer element. The silencing influence 
of this region has been shown previously [29—31] in different 
cells. On the basis of studies on one ICAM-1-positive cell line 
that lacked silencer activity and one ICAM-1-negative cell that 
demonstrated activity, Cornelius et al. [30] concluded that the 
region from positions -1163 to -277 correlates with the 
ICAM-1 phenotype and is necessary and sufficient to mediate
constitutive ICAM-1 expression. The fact that we found an en­
hancer upstream of this silencer and the analysis of a large panel 
of positive and negative cells presented here clearly indicates 
that the two patterns of reporter-gene activity observed for the 
region between —339 and —174 bp do not correlate either with 
the cell type or with the absence or presence of ICAM-1 mRNA 
or protein. The analysis of additional constructs in Mel JuSo 
allowed the silencer region to be localised between positions 
-339 and —290. Computer-aided analysis of this region re­
vealed, around position —313, similarities to silencers found in 
a variety of different promoters (Table 2), supporting the impor­
tance of this region. Although type-B cells generally expressed 
lower absolute levels of ICAM-1 promoter activity than type-A 
cells, a B-type pattern was also observed in cells with high abso­
lute activity (e.g. HepG2) and the type-A pattern was observed 
in cells with low promoter activity (e.g. A-375, H4 and HMCB), 
indicating that the pattern is not dependent on the absolute repor­
ter-gene activity.
Additional studies carried out in Mel JuSo (Fig. 3) revealed 
two further regions important in the regulation of the human 
ICAM-1 gene. The region between positions —277 and —227 
(Fig. 3) was found to enhance promoter activity by a factor of 
two in comparison to pIC-174. A search for transcription-factor- 
binding motifs in this region revealed the presence of a potential 
binding site for AP-2 and for NF-/cB [41]. Deletion of the DNA 
from positions —108 to —34, which contains consensus motifs 
for Spl and AP-2, led to a loss of greater than 90% of the
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promoter activity in Mel JuSo and, as previously described [28], 
in cell line 293, suggesting an important role of Spl or AP-2 
in regulating constitutive ICAM-1 expression. In-vitro binding 
assays did show specific binding of Spl to its putative site in all 
examined cell lines (unpublished observations), underscoring the 
importance of this region.
ICAM-1 contains two TATA boxes [29]. In Mel JuSo cells, 
both TATA boxes apparently can be used for the initiation of 
ICAM-1 transcription. Deletion of the upstream TATA box 
(Fig. 3, pIC-339 compared to pIC-174) did not decrease the ex­
pression of luciferase reporter-gene constructs (in as far as this 
was detectable because of the overlapping silencer), indicating 
that transcription is mainly initiated from the downstream start 
site under constitutive conditions. However, deletion of the 
downstream TATA box (TATA1) from pIC-1352, a construct 
containing both TATA boxes, did not alter promoter activity 
(pIC-1352 compared to pIC-l352/ITATA1), indicating that, in 
Mel JuSo, the function of the downstream start site can be re­
placed by the upstream start site, and suggesting that the silencer 
functions not only via the downstream TATA box.
Although the presence or absence of an active silencer in the 
region from positions -339 to —290 could be used to divide 
the cells examined into two groups, this was not associated with 
ICAM-1 mRNA or cell surface protein expression. Nevertheless, 
a relationship between ICAM-1 expression and silencer activity 
was observed. Silencer activity was detectable only in cells that 
were ICAM-1 negative or that constitutively expressed high lev­
els of ICAM-1 (type-A cells). All of the cells that showed no 
silencer activity (type-B cells) expressed low but detectable lev­
els of ICAM-1. These results suggest that at least two distinct 
mechanisms are involved in the regulation of constitutive 
ICAM-1 expression. One mechanism, that appears to be associ­
ated with inactivity of the silencer region, leads to a low level 
of constitutive expression such as has been observed in a variety 
of cells in vivo and in vitro [3, 13 — 16] and that may allow 
ICAM-1 to be rapidly upregulated by cytokines. The second is 
responsible for the high constitutive levels of ICAM-1, such as 
is found in macrophages and in some human tumours [21, 23, 
24], This regulation pattern is associated with the presence of 
an active silencer between positions —339 and —290 that is 
overridden by the enhancer binding between positions —2400 
and -1352.
The transfected full-length 15.5-kb clone HWB 3R1, con­
taining all exons and introns, could be expressed in several 
ICAM-1-negative cell lines, suggesting that transcription factors 
acting on regions outside of HWB 3R1 are responsible for con­
stitutive expression, as shown for other genes [44, 45]. This 
could explain why we failed to identify the region conferring 
constitutive ICAM-1 expression. Clearly, interactions not imi­
tated by our in vitro system may also be involved. Jaiswal et al. 
[46] detected that limited amounts of tissue-specific factors can 
be easier titrated out in transient than in stable transfectants. An 
influence of balanced transcription factors were found in both 
multiple histocompatability complex class I, where a balance of 
positive and negative transcription factors seems to regulate its 
expression [47], as well as in class II, where inhibition of tran­
scription is dependent on the amount of inhibitor Drl [48]. Pre­
liminary results (unpublished observations) suggest that DNA 
methylation, as observed in other genes [49, 50], could partici­
pate in regulating constitutive ICAM-1 expression.
The studies reported here reveal important elements influ­
encing ICAM-1 expression and indicate that ICAM-1 is regu­
lated by a complex interaction between positive and negative 
elements. They also suggest that additional elements outside the 
examined region and features such as the methylation pattern
play an important role in determining the constitutive expression 
of ICAM-1.
This work was supported by a grant from the Deutsche Fors chungs- 
gemeinschaft [Sonderforschungsbereich 217(A3)].
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